Geneva, Switzerland
EBAMed, founded in 2018, is a pioneering company based in Switzerland, specializing in the health care sector. With their slogan, "Ultrasound Guidance during Radio Ablation Treatment of Cardiac Arrhythmias," they are targeting an innovative solution for non-invasive cardiac treatment.
Their product, CardioKit, provides advanced functionalities including target position verification, cardiac motion monitoring, and both respiratory and cardiac gating, which collectively represent a novel approach in treating cardiac arrhythmias. This solution positions EBAMed well in a sector that increasingly values non-invasive interventions.
In their latest funding round on 27 June 2023, EBAMed secured a noteworthy €14.35M Series A investment, backed by key players like the European Innovation Council, LIFTT, Mayo Clinic, Occident, Panakes Partners, and EFI Lake Geneva Ventures. This substantial investment highlights strong confidence in their technology and potential for growth.
